Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Peanutbudderon Jan 14, 2018 1:31pm

111 Views

Post# 27353582

RE:RE:RE:RE:Salzman shares.. Dec 22 & these from last Friday.

Gilbert, thank you for the correction. Maybe perhaps it would be better for those shares to be sold at a lower price so they get absorbed by the market and help build the baseline. Perhaps 500k shares at 0.50 could cause a panic selloff. Either way, I think it helps consolidation greatly and doesn't make me worry that the SP will jump off a cliff at any point. However the whole sector is still being corrected and alot of people still selling off with all this sessions nonsense. Either way thanks for the time and opinions Gilbert.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!